Kinins promote B2 receptor endocytosis and delay constitutive B1 receptor endocytosis

Johan Enquist, Carl Skröder, Jennifer Whistler, L. M.Fredrik Leeb-Lundberg

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Upon sustained insult, kinins are released and many kinin responses, such as inflammatory pain, adapt from a B2 receptor (B2R) type in the acute phase to a B1 receptor (B1R) type in the chronic phase. In this study, we show that kinins modulate receptor endocytosis to rapidly decrease B2R and increase B1R on the cell surface. B2Rs, which require agonist for activity, are stable plasma membrane components without agonist but recruit β-arrestin 2, internalize in a clathrin-dependent manner, and recycle rapidly upon agonist treatment. In contrast, B1Rs, which are inducible and constitutively active, constitutively internalize without agonist via a clathrin-dependent pathway, do not recruit β-arrestin 2, bind G protein-coupled receptor sorting protein, and target lysosomes for degradation. Agonist delays B1R endocytosis, thus transiently stabilizing the receptor. Most of the receptor trafficking phenotypes are transplantable from one receptor to the other through exchange of the C-terminal receptor tails, indicating that the tails contain epitopes that are important for the binding of protein partners that participate in the endocytic and postendocytic receptor choices. It is noteworthy that the agonist delay of B1R endocytosis is not transplanted to the B2R via the B1R tail, suggesting that this property of the B1R requires another domain. These events provide a rapid kinin-dependent mechanism for 1) regulating the constitutive B1R activity and 2) shifting the balance of accessible receptors in favor of B1R.

Original languageEnglish (US)
Pages (from-to)494-507
Number of pages14
JournalMolecular Pharmacology
Volume71
Issue number2
DOIs
StatePublished - Feb 1 2007
Externally publishedYes

Fingerprint

Kinins
Endocytosis
Clathrin
Cell Surface Receptors
Protein Transport
G-Protein-Coupled Receptors
Lysosomes
Epitopes
Carrier Proteins
Cell Membrane
Phenotype
Pain
beta-Arrestin 1
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Kinins promote B2 receptor endocytosis and delay constitutive B1 receptor endocytosis. / Enquist, Johan; Skröder, Carl; Whistler, Jennifer; Leeb-Lundberg, L. M.Fredrik.

In: Molecular Pharmacology, Vol. 71, No. 2, 01.02.2007, p. 494-507.

Research output: Contribution to journalArticle

Enquist, Johan ; Skröder, Carl ; Whistler, Jennifer ; Leeb-Lundberg, L. M.Fredrik. / Kinins promote B2 receptor endocytosis and delay constitutive B1 receptor endocytosis. In: Molecular Pharmacology. 2007 ; Vol. 71, No. 2. pp. 494-507.
@article{62cdf699de5c4c50b4dc0ece700f55b1,
title = "Kinins promote B2 receptor endocytosis and delay constitutive B1 receptor endocytosis",
abstract = "Upon sustained insult, kinins are released and many kinin responses, such as inflammatory pain, adapt from a B2 receptor (B2R) type in the acute phase to a B1 receptor (B1R) type in the chronic phase. In this study, we show that kinins modulate receptor endocytosis to rapidly decrease B2R and increase B1R on the cell surface. B2Rs, which require agonist for activity, are stable plasma membrane components without agonist but recruit β-arrestin 2, internalize in a clathrin-dependent manner, and recycle rapidly upon agonist treatment. In contrast, B1Rs, which are inducible and constitutively active, constitutively internalize without agonist via a clathrin-dependent pathway, do not recruit β-arrestin 2, bind G protein-coupled receptor sorting protein, and target lysosomes for degradation. Agonist delays B1R endocytosis, thus transiently stabilizing the receptor. Most of the receptor trafficking phenotypes are transplantable from one receptor to the other through exchange of the C-terminal receptor tails, indicating that the tails contain epitopes that are important for the binding of protein partners that participate in the endocytic and postendocytic receptor choices. It is noteworthy that the agonist delay of B1R endocytosis is not transplanted to the B2R via the B1R tail, suggesting that this property of the B1R requires another domain. These events provide a rapid kinin-dependent mechanism for 1) regulating the constitutive B1R activity and 2) shifting the balance of accessible receptors in favor of B1R.",
author = "Johan Enquist and Carl Skr{\"o}der and Jennifer Whistler and Leeb-Lundberg, {L. M.Fredrik}",
year = "2007",
month = "2",
day = "1",
doi = "10.1124/mol.106.030858",
language = "English (US)",
volume = "71",
pages = "494--507",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Kinins promote B2 receptor endocytosis and delay constitutive B1 receptor endocytosis

AU - Enquist, Johan

AU - Skröder, Carl

AU - Whistler, Jennifer

AU - Leeb-Lundberg, L. M.Fredrik

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Upon sustained insult, kinins are released and many kinin responses, such as inflammatory pain, adapt from a B2 receptor (B2R) type in the acute phase to a B1 receptor (B1R) type in the chronic phase. In this study, we show that kinins modulate receptor endocytosis to rapidly decrease B2R and increase B1R on the cell surface. B2Rs, which require agonist for activity, are stable plasma membrane components without agonist but recruit β-arrestin 2, internalize in a clathrin-dependent manner, and recycle rapidly upon agonist treatment. In contrast, B1Rs, which are inducible and constitutively active, constitutively internalize without agonist via a clathrin-dependent pathway, do not recruit β-arrestin 2, bind G protein-coupled receptor sorting protein, and target lysosomes for degradation. Agonist delays B1R endocytosis, thus transiently stabilizing the receptor. Most of the receptor trafficking phenotypes are transplantable from one receptor to the other through exchange of the C-terminal receptor tails, indicating that the tails contain epitopes that are important for the binding of protein partners that participate in the endocytic and postendocytic receptor choices. It is noteworthy that the agonist delay of B1R endocytosis is not transplanted to the B2R via the B1R tail, suggesting that this property of the B1R requires another domain. These events provide a rapid kinin-dependent mechanism for 1) regulating the constitutive B1R activity and 2) shifting the balance of accessible receptors in favor of B1R.

AB - Upon sustained insult, kinins are released and many kinin responses, such as inflammatory pain, adapt from a B2 receptor (B2R) type in the acute phase to a B1 receptor (B1R) type in the chronic phase. In this study, we show that kinins modulate receptor endocytosis to rapidly decrease B2R and increase B1R on the cell surface. B2Rs, which require agonist for activity, are stable plasma membrane components without agonist but recruit β-arrestin 2, internalize in a clathrin-dependent manner, and recycle rapidly upon agonist treatment. In contrast, B1Rs, which are inducible and constitutively active, constitutively internalize without agonist via a clathrin-dependent pathway, do not recruit β-arrestin 2, bind G protein-coupled receptor sorting protein, and target lysosomes for degradation. Agonist delays B1R endocytosis, thus transiently stabilizing the receptor. Most of the receptor trafficking phenotypes are transplantable from one receptor to the other through exchange of the C-terminal receptor tails, indicating that the tails contain epitopes that are important for the binding of protein partners that participate in the endocytic and postendocytic receptor choices. It is noteworthy that the agonist delay of B1R endocytosis is not transplanted to the B2R via the B1R tail, suggesting that this property of the B1R requires another domain. These events provide a rapid kinin-dependent mechanism for 1) regulating the constitutive B1R activity and 2) shifting the balance of accessible receptors in favor of B1R.

UR - http://www.scopus.com/inward/record.url?scp=33846428788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846428788&partnerID=8YFLogxK

U2 - 10.1124/mol.106.030858

DO - 10.1124/mol.106.030858

M3 - Article

C2 - 17110500

AN - SCOPUS:33846428788

VL - 71

SP - 494

EP - 507

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 2

ER -